454 Life Sciences Ships First Genome Sequencer FLX System™ to Roche Diagnostics
News Jan 11, 2007
CuraGen Corporation's majority owned subsidiary 454 Life Sciences Corporation has announced that the new high throughput Genome Sequencer FLX System™ (GS FLX) has been shipped to its marketing partner Roche Diagnostics in preparation for a first quarter 2007 launch.
According to 454 Life Sciences, the GS FLX improves upon its predecessor, the Genome Sequencer 20™ System, across several key aspects including longer reads, higher throughput, and greatly improved single read accuracy. The system was developed by 454 Life Sciences in cooperation with Roche Diagnostics.
The enhanced read length and accuracy supports an even broader range of applications which yield deep biological content. Researchers using the GS FLX will have expanded capacity to discover and develop comprehensive solutions for complex research programs. The Genome Sequencer 20 systems that are already in use can easily be upgraded on-site to GS FLX.
"We are excited about delivering the GS FLX system to our sales and marketing partner Roche in preparation for a Q1 2007 launch," said Christopher McLeod, President and CEO of 454 Life Sciences.
"Feedback from early adopter sites has been very positive due to longer read lengths, increased throughput per run and very high single read accuracy over 200 bases. The GS FLX offers high throughput sequencing with single read accuracy equivalent to traditional Sanger sequencing."
Using EBX reagents, researchers have converted the C-terminal carboxylic acid of peptides into a carbon-carbon triple bond - an alkyne (in chemical jargon a "decarboxylative alkynylation"). The alkyne moiety is a very valuable functional group that can be used to further modify the peptides.READ MORE